AURX — Nuo Therapeutics, Inc. Dilution Risk Tracker

Nuo Therapeutics, Inc. (AURX) has a DilutionScore of 65/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 13, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 6.4M outstanding warrants for AURX. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: AURX has approximately 2 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for AURX in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for AURX alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.